A phase 1 study of BPI-002, an oral CTLA-4 inhibitor in Cancer.

Trial Profile

A phase 1 study of BPI-002, an oral CTLA-4 inhibitor in Cancer.

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs BPI 002 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Apr 2018 New trial record
    • 03 Apr 2018 According to a BeyondSpring Pharmaceuticals media release, company plans this study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top